Patents by Inventor Alessia Fornoni
Alessia Fornoni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230338412Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.Type: ApplicationFiled: September 21, 2022Publication date: October 26, 2023Applicant: L&F RESEARCH LLCInventors: Alessia FORNONI, Sandra MERSCHER-GOMEZ
-
Patent number: 11344604Abstract: Disclosed herein is a method of treating or preventing renal disease in a subject suffering from Alport Syndrome, as well a method of treating or preventing chronic kidney disease. The method comprises administering to a subject in need thereof an effective amount of human apolipoprotein M.Type: GrantFiled: July 12, 2019Date of Patent: May 31, 2022Assignee: UNIVERSITY OF MIAMIInventors: Alessia Fornoni, Sandra Merscher
-
Publication number: 20210275632Abstract: Disclosed herein is a method of treating or preventing renal disease in a subject suffering from Alport Syndrome, as well a method of treating or preventing chronic kidney disease. The method comprises administering to a subject in need thereof an effective amount of human apolipoprotein M.Type: ApplicationFiled: July 12, 2019Publication date: September 9, 2021Inventors: Alessia Fornoni, Sandra Merscher
-
Publication number: 20210275514Abstract: The present disclosure relates to ABCA1 inducer compounds for use in treating kidney disorders, and in particular, chronic kidney diseases, glomerular diseases or proteinuric kidney diseases such as Alport syndrome, focal segmental glomerulosclerosis, and diabetic kidney disease.Type: ApplicationFiled: March 19, 2021Publication date: September 9, 2021Inventor: Alessia FORNONI
-
Publication number: 20210228616Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.Type: ApplicationFiled: January 22, 2021Publication date: July 29, 2021Applicant: L&F Research LLCInventors: Alessia Fornoni, Sandra Merscher-Gomez
-
Publication number: 20210186930Abstract: Disclosed herein is a method of treating renal disease in a subject suffering from Alport Syndrome or chronic kidney disease comprising administering ezetimibe (optionally in combination with ramipril) to the subject in an amount effective to treat the renal disease in the subject.Type: ApplicationFiled: May 14, 2019Publication date: June 24, 2021Inventors: Alessia Fornoni, Sandra Merscher
-
Patent number: 10980828Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.Type: GrantFiled: December 20, 2018Date of Patent: April 20, 2021Assignee: L & F Research LLCInventors: Alessia Fornoni, Sandra Merscher-Gomez
-
Patent number: 10765697Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.Type: GrantFiled: December 20, 2018Date of Patent: September 8, 2020Assignee: L & F RESEARCH LLCInventors: Alessia Fornoni, Sandra Merscher-Gomez
-
Publication number: 20200085810Abstract: The present disclosure relates to ABCA1 inducer compounds for use in treating kidney disorders, and in particular, chronic kidney diseases, glomerular diseases or proteinuric kidney diseases such as Alport syndrome, focal segmental glomerulosclerosis, and diabetic kidney disease.Type: ApplicationFiled: July 25, 2019Publication date: March 19, 2020Inventor: Alessia FORNONI
-
Publication number: 20190262385Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.Type: ApplicationFiled: December 20, 2018Publication date: August 29, 2019Applicant: L&F Research LLCInventors: Alessia Fornoni, Sandra Merscher-Gomez
-
Publication number: 20190125780Abstract: Assays, methods and kits for predicting a subjects (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.Type: ApplicationFiled: December 20, 2018Publication date: May 2, 2019Applicant: L&F RESEARCH LLCInventors: Alessia FORNONI, Sandra MERSCHER-GOMEZ
-
Patent number: 10195227Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.Type: GrantFiled: April 12, 2013Date of Patent: February 5, 2019Assignee: L&F Research LLCInventors: Alessia Fornoni, Sandra Merscher-Gomez
-
Patent number: 10183038Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.Type: GrantFiled: December 14, 2015Date of Patent: January 22, 2019Assignee: L&F Research LLCInventors: Alessia Fornoni, Sandra Merscher-Gomez
-
Patent number: 10052345Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the afore-mentioned disorders.Type: GrantFiled: October 14, 2011Date of Patent: August 21, 2018Assignee: University of MiamiInventors: Alessia Fornoni, George William Burke, Sandra Merscher-Gomez
-
Publication number: 20160220600Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.Type: ApplicationFiled: December 14, 2015Publication date: August 4, 2016Inventors: Alessia Fornoni, Sandra Merscher-Gomez
-
Publication number: 20150065457Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.Type: ApplicationFiled: April 12, 2013Publication date: March 5, 2015Applicant: L&F HEALTH LLCInventors: Alessia Fornoni, Sandra Merscher-Gomez
-
Publication number: 20140302065Abstract: Methods and compositions are provided for diagnosing and treating a diabetic kidney disease (DKD) in an individual. In aspects of the methods, the levels of soluble circulating urokinase receptor (suPAR) in the blood are measured to predict a DKD, diagnose a DKD, or provide a prognosis pertaining to a DKD. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided.Type: ApplicationFiled: October 30, 2012Publication date: October 9, 2014Applicant: THE UNIVERSITY OF MIAMIInventors: Alessia Fornoni, Jochen Reiser, Changli Wei, Sandra Monika Merscher-Gomez
-
Publication number: 20130202601Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the afore-mentioned disorders.Type: ApplicationFiled: October 14, 2011Publication date: August 8, 2013Inventors: Alessia Fornoni, George William Burke, Sandra Merscher-Gomez